Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 3

Featured

Random
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Natural Medicine Advisory Bulletin 9

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Psyence Group Announces Cantheon Capital Private Placement

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

Tripping the Reward Circuit: Psychedelics for Substance Use Disorders

Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies...

Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely...

PT374 – Personalizing Psychedelic Integration

Mydecine Announces Reverse Stock-Split

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...

March 2026 Psychedelic Bill Round-up

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

1234...329Page 3 of 329

EDITOR PICKS

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©